THERAPEUTIC PLATFORM
Delivery Technology
Silence possesses a range of proprietary siRNA delivery technologies to achieve the goal of systemic delivery of RNA therapeutics
Silence’s sophisticated and flexible delivery technologies provide the company with unmatched potential to develop solutions for delivering RNAi molecules to a wide variety of disease tissue. This versatility positions Silence to be a partner of choice for pharmaceutical and biotechnology companies currently working in, or seeking to enter, the RNAi field. |
 |
Silence has developed proprietary lipid-based siRNA delivery technology platforms, also known as siRNA-lipoplex technologies. Our unique platforms are based on proprietary lipid components which embed siRNA into lipid-bi-layer particles. The siRNA combined with our developed lipid moieties containing cationic, fusogenic and PEGylated lipids, form nanoparticle structures with various pharmacodynamic properties, enabling functional delivery to various cell types upon systemic administation.
The following delivery systems are currently available for RNAi in following target structures: |
||
| AtuPLEX™ | - | The AtuPLEX system broadly delivers siRNA to vascular endothelial cells of various organs |
| DACC | - | The DACC system specifically delivers siRNA to vascular endothelial cells of the lung |
| DBTC | - | The DBTC system specifically delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma |